Evidence map›Paper›PMID 36097251›Full record

SynthesisCNS drugs2022

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Niloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, Yena Lee, Joshua D Rosenblat, Kayla M Teopiz, Leanna M W Lui, Mehala Subramaniapillai, Kangguang Lin, Flora Nasri and 7 more

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review.Journal of psychopharmacology (Oxford, England) · 2025
    Pooled it
  4. Pooled it
  5. Review
  6. Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 7 countries.

Niloufar PouyanDepartment of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital, Zurich, Switzerland. npouyan@umich.edu.ORCID http://orcid.org/0000-0003-4606-3528
Zahra Halvaei KhankahdaniFaculty of Pharmacy, Islamic Azad University of Medical Sciences, Tehran, Iran.
Farnaz Younesi SisiFaculty of Pharmacy, Islamic Azad University of Medical Sciences, Tehran, Iran.
Yena LeeMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.
Joshua D RosenblatMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.
Kayla M TeopizMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.
Leanna M W LuiMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0148-5455
Mehala SubramaniapillaiBrain and Cognition Discovery Foundation, Toronto, ON, Canada.
Kangguang LinDepartment of Affective Disorders, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Flora NasriMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0627-3558
Nelson RodriguesMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.
Hartej GillMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-3568-8816
Orly LipsitzMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-9110-7951
Bing CaoSchool of Psychology and Key Laboratory of Cognition and Personality (Ministry of Education), Southwest University, Chongqing, People's Republic of China.ORCID http://orcid.org/0000-0001-5963-2676
Roger HoDepartment of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0001-9629-4493
David CastleDepartment of Psychiatry, Centre for Complex Interventions, Centre for Addictions and Mental Health, University of Toronto, Toronto, ON, Canada.
Roger S McIntyreMood Disorders Psychopharmacology Unit (MDPU), University Health Network, Toronto, ON, Canada.
University Health Network · CAIslamic Azad University Medical Branch of Tehran · IRBrain and Cognition Discovery Foundation · CACentre for Addiction and Mental Health · CAGuangzhou Medical University · CNNational University of Singapore · SGSouthwest University · CNUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of select psychedelics (e.g., psilocybin) suggest that their effects are transdiagnostic. In this review, we exploit the Research Domain Criteria (RDoC) transdiagnostic framework, to synthesize extant literature on psilocybin.

objectiveWe aimed to identify RDoC-based effects of psilocybin and vistas for future mechanistic and interventional research.

methodsA systematic search in electronic databases (i.e., PubMed, Scopus, PsycINFO, and Web of Science) performed in January and February 2021 identified English articles published between 1990 and 2020 reporting the effects of psilocybin on mental health measures. Data from included articles were retrieved and organized according to the RDoC bio-behavioral matrix and its constituent six main domains, namely: positive valence systems, negative valence systems, cognitive systems, social processes, sensorimotor systems, and arousal and regulatory systems.

resultsThe preponderance of research with psilocybin has differentially reported beneficial effects on positive valence systems, negative valence system, and social process domains. The data from the included studies support both short-term (23 assessments) and long-term (15 assessments) beneficial effects of psilocybin on the positive valence systems. While 12 of the extracted outcome measures suggest that psilocybin use is associated with increases in the "fear" construct of the negative valence systems domain, 19 findings show no significant effects on this construct, and seven parameters show lowered levels of the "sustained threat" construct in the long term. Thirty-four outcome measures revealed short-term alterations in the social systems' construct namely, "perception and understanding of self," and "social communications" as well as enhancements in "perception and understanding of others" and "affiliation and attachment". The majority of findings related to the cognitive systems' domain reported dyscognitive effects. There have been relatively few studies reporting outcomes of psilocybin on the remaining RDoC domains. Moreover, seven of the included studies suggest the transdiagnostic effects of psilocybin. The dashboard characterization of RDoC outcomes with psilocybin suggests beneficial effects in the measures of reward, threat, and arousal, as well as general social systems.

conclusionsPsilocybin possesses a multi-domain effectiveness. The field would benefit from highly rigorous proof-of-mechanism research to assess the effects of psilocybin using the RDoC framework. The combined effect of psilocybin with psychosocial interventions with RDoC-based outcomes is a priority therapeutic vista.

Indexed as

HallucinogensPsilocybinHumansHallucinogensPsilocybin

Identifiers

PMID36097251
PMCPMC9550777
OpenAlexW4295449270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.